Ligandal provides novel peptide nanoparticles and targeted drug delivery technologies for advanced therapies including gene editors, viral vectors, and cellular therapies. We offer transformational licensing solutions for unmet needs to life sciences, pharmaceutical, biotech, and drug discovery companies. We help our partners discover and develop a new form of targeted delivery for their complex therapies. Ligandal has adopted a well-defined approach to partnering that aims to deliver solutions and add value to partners, covering a wide range of products and therapeutic areas using our proprietary AI/peptide target discovery platform technology.
We are able to reduce off-target effects, enhance bioavailability, promote targeted cellular delivery, and create patentable formulations.
We are able to reduce off-target effects, enhance bioavailability, promote targeted cellular delivery, and create patentable formulations.
Advanced targeted delivery
Using our unique AI/Peptide discovery platform, we are able to customize a targeted drug delivery product tailored to a particular cell or tissue of interest.
This is particularly useful for advanced medicines including:
This is particularly useful for advanced medicines including:
CRISPRGenome Engineering
|
Viral vaccinesVaccines & VLPs
|
Nucleic AcidsRNA & DNA Vectors
|
Viral vectorsAAVs/AdVs/LVPs/LVVs
|
BIoPHarmaAntibodies & Peptides
|
cellular therapiesCAR-T/TILs/TAMs
|
Further partnering and licensing opportunities are available.
Email partnerships@ligandal.com for more information.
Peptide Nanoparticles for Targeted drug delivery
"Ligandal is akin to the invention of GPS and shipping routes for molecular delivery technologies."“